ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
34 announcements
Dr. Agarwal's Health Care Limited held its 16th AGM on September 21, 2026. Shareholders approved all agenda items, including financial statements and director re-appointments.
Dr. Agarwal's Health Care Limited has issued the notice for its Sixteenth Annual General Meeting, scheduled for September 21, 2026, alongside its FY 2025-26 Annual Report.
Dr. Agarwals Eye Hospital, a subsidiary, launched the World's First Pinhole Pupilloplasty Centre in Chennai. This facility advances specialized surgical treatments for complex corneal disorders.
Catalyst Trusteeship Limited reported the creation of a pledge over 7,538,303 equity shares of Dr. Agarwal's Health Care Limited, representing 2.38% of its capital.
DB International Trust disclosed a partial release of pledge and disposal of 24,160,000 shares in Dr. Agarwal’s Health Care Ltd. The disclosure complies with Reg 29(2).
Catalyst Trusteeship Limited reported a release of pledge over 3,16,98,303 equity shares of Dr. Agarwal's Health Care Limited. The transaction pertains to a USD 100 million facility.
ICICI Prudential Mutual Fund acquired 1,69,99,999 shares of Dr. Agarwal's Health Care Limited through the open market. This acquisition represents a 5.36% stake in the company.
Dr. Agarwals Health Care will incorporate a new subsidiary, Orbit Health Care Services (Nigeria) Ltd, for Rs.0.70 Crore. This investment supports its Nigerian eye care expansion.
Dr Agarwals Health Care has appointed S.R. Batliboi & Associates LLP as statutory auditor, KPMG as internal auditor, and re-appointed B Y & Associates as cost auditor.
Dr. Agarwal's Health Care Ltd appointed S.R. Batliboi & Associates as Statutory Auditor, KPMG as Internal Auditor, and re-appointed B Y & Associates as Cost Auditor.
Dr. Agarwal’s reported strong Q1FY27 results with revenue of ₹614 Cr and EBITDA of ₹177 Cr. Strategy focuses on aggressive 'Greenfield' expansion and hub-and-spoke scalability across India and Africa.
Dr. Agarwals Health Care Ltd reported revenue from operations of ₹614 Cr (+26.0% YoY) and net profit of ₹55 Cr (+44.4% YoY) for Q1 FY27.
Dr. Agarwal's Health Care Ltd will hold a board meeting on August 4, 2026, to approve financial results and host an earnings conference call.
Dr Agarwals Health Care allotted 43,155 equity shares under its ESOP/ESPS scheme. Post-allotment, the company's paid-up share capital increased to Rs 31,70,26,183.
Dr. Agarwal's Health Care allotted 43,155 equity shares under its 2022 ESOP scheme. Total paid-up capital increased to Rs.31.70 Crore following this allotment.
Dr. Agarwal's Eye Institute clarified SBO details for shareholding pattern, noting PAN and nationality for Dr. Adil Agarwal only. No financial impact is associated with the update.
Dr. Agarwal's Health Care Ltd held a creditor meeting for its amalgamation with Dr. Agarwal's Eye Hospital. The meeting, convened by NCLT, considered the scheme under Companies Act provisions.
Dr. Agarwal's Health Care Ltd held an NCLT-convened shareholder meeting to approve its amalgamation with Dr. Agarwal's Eye Hospital Ltd. The meeting was convened to pass a special majority resolution under the Companies Act.
CRISIL reaffirmed and withdrew its AA- rating on Dr. Agarwal's debt facilities. The withdrawal follows a company request with lender consent; ICRA continues to rate the facilities.
Dr. Agarwal's Health Care Limited convened an NCLT-ordered shareholder meeting for July 02, 2026, to approve its amalgamation with Dr. Agarwal's Eye Hospital Limited. The merger aims to consolidate eye care operations and improve capital efficiency.
Dr. Agarwal's Health Care completed incorporating a new wholly owned subsidiary in Ethiopia. The ₹2,000,000 Crore transaction marks the firm's strategic entry into the Ethiopian market.
Dr. Agarwal’s reported strong FY26 performance, crossing INR 2,000cr revenue milestone with significant network expansion and EBITDA margin improvement to 28.9%.
Dr. Agarwal’s Health Care incorporated Orbit Health Care ETH PLC in Ethiopia via a ₹1.90 Crore investment. The new entity becomes an indirect wholly owned subsidiary.
Dr. Agarwal's Health Care Limited allotted 25,240 equity shares under its ESOP scheme. The issuance marginally increases the company's total paid-up share capital.
Dr. Agarwal's Health Care allotted 25,240 shares under its ESOP scheme, valued at ₹0.33 Crore. The allotment increases the company's total paid-up equity share capital.
Dr. Agarwals reported 21% income growth in FY26, driven by aggressive network expansion (57 new facilities) and clinical excellence.
Dr. Agarwals Health Care Ltd reported revenue from operations of ₹564.1 Cr (+22.6% YoY) and net profit of ₹50 Cr (+17.6% YoY) for Q4 FY26.
Dr. Agarwal’s Health Care reported FY2026 total income of ₹2125.00 Crore, a 20.9% year-on-year growth. Net profit surged 52.4% to ₹168 Crore alongside significant network expansion.
Dr. Agarwals Health Care received a ₹20.50 Crore GST show cause notice for FY 2023-24. The company is evaluating legal steps to respond within thirty days.
Dr. Agarwal’s Health Care scheduled a board meeting for May 21, 2026, to approve annual financial results. An earnings call will follow the meeting same day.